228 related articles for article (PubMed ID: 35590037)
1. Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP).
Burden AD; Mrowietz U; Skalicky AM; Rentz AM; Esser D; Gloede T; Thoma C; Menter A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1367-1381. PubMed ID: 35590037
[TBL] [Abstract][Full Text] [Related]
2. The content validity of the PSS in patients with plaque psoriasis.
Rentz AM; Skalicky AM; Burslem K; Becker K; Kaschinski D; Esser D; Revicki DA
J Patient Rep Outcomes; 2017; 1(1):4. PubMed ID: 29757301
[TBL] [Abstract][Full Text] [Related]
3. Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
Burden AD; Bissonnette R; Anatchkova M; Budhiarso I; Skalicky AM; Liberato ACS; Hu N; Thoma C; Gloede T; Kohlmann T; Lebwohl MG
J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1383-1390. PubMed ID: 38334243
[TBL] [Abstract][Full Text] [Related]
4. Validation of the PROFAD-SSI-SF in Patients with Primary Sjögren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses.
Raymond K; Maher S; Saucier CD; O'Connor M; Yarlas A; Kosinski M; Chen WH; Gairy K
Rheumatol Ther; 2023 Feb; 10(1):95-115. PubMed ID: 36227531
[TBL] [Abstract][Full Text] [Related]
5. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses.
Armstrong AW; Edson-Heredia E; Naegeli AN; Burge R; Poon JL; Anatchkova M; Sun L; Zhu B; Wyrwich KW
J Dermatolog Treat; 2020 Aug; 31(5):452-459. PubMed ID: 31157576
[No Abstract] [Full Text] [Related]
6. The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).
Gottlieb AB; Kirby B; Ryan C; Naegeli AN; Burge R; Potts Bleakman A; Anatchkova MD; Yosipovitch G
Dermatol Ther (Heidelb); 2018 Mar; 8(1):45-56. PubMed ID: 29204893
[TBL] [Abstract][Full Text] [Related]
7. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey.
Reisner DV; Johnsson FD; Kotowsky N; Brunette S; Valdecantos W; Eyerich K
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):65-71. PubMed ID: 35061229
[TBL] [Abstract][Full Text] [Related]
8. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.
Martin ML; McCarrier KP; Chiou CF; Gordon K; Kimball AB; Van Voorhees AS; Gottlieb AB; Huang X; Globe D; Chau D; Viswanathan HN; Kricorian G
J Dermatolog Treat; 2013 Aug; 24(4):255-60. PubMed ID: 23249143
[TBL] [Abstract][Full Text] [Related]
9. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups.
Globe D; Bayliss MS; Harrison DJ
Health Qual Life Outcomes; 2009 Jul; 7():62. PubMed ID: 19580674
[TBL] [Abstract][Full Text] [Related]
10. The experience of pain and redness in patients with moderate to severe plaque psoriasis.
Martin ML; Gordon K; Pinto L; Bushnell DM; Chau D; Viswanathan HN
J Dermatolog Treat; 2015 Oct; 26(5):401-5. PubMed ID: 25822169
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study.
Bellinato F; Gisondi P; Marzano AV; Piaserico S; De Simone C; Damiani G; Argenziano G; Venturini M; Dapavo P; Costanzo A; Megna M; Prignano F; Burlando M; Satolli F; Carugno A; Pezzolo E; Romanelli M; Cuccia A; Girolomoni G
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112652
[TBL] [Abstract][Full Text] [Related]
12. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review.
Choon SE; De La Cruz C; Wolf P; Jha RK; Fischer KI; Goncalves-Bradley DC; Hepworth T; Marshall SR; Gottlieb AB
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):265-280. PubMed ID: 37750484
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis [Podcast].
Merola JF; Amin AZ
Clin Cosmet Investig Dermatol; 2024; 17():539-545. PubMed ID: 38482176
[TBL] [Abstract][Full Text] [Related]
15. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion.
Bachelez H; Barker J; Burden AD; Navarini AA; Krueger JG
Expert Rev Clin Immunol; 2022 Oct; 18(10):1033-1047. PubMed ID: 36062811
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
[TBL] [Abstract][Full Text] [Related]
17. Qualitative Research to Understand the Patient Experience and Evaluate Content Validity of the Chronic Ocular Pain Questionnaire (COP-Q).
Karpecki PM; Findley A; Sloesen BJ; Hodson N; Bentley S; Arbuckle R; O'Brien P; Montecchi-Palmer M; Naujoks C; Hamrah P
Ophthalmol Ther; 2024 Feb; 13(2):615-633. PubMed ID: 38183618
[TBL] [Abstract][Full Text] [Related]
18. Content Validation of the ATTR Amyloidosis Patient Symptom Survey: Findings from Patient and Clinician Cognitive Debriefing Interviews.
Rizio AA; Broderick LE; White MK; Quock TP
Patient Relat Outcome Meas; 2020; 11():149-160. PubMed ID: 32904695
[TBL] [Abstract][Full Text] [Related]
19. Clinical Disease Measures in Generalized Pustular Psoriasis.
Burden AD; Choon SE; Gottlieb AB; Navarini AA; Warren RB
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):39-50. PubMed ID: 35061231
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.
Wolf P; Ceovic R; Conrad C; Falkensteiner K; Graier T; Kołt-Kamińska M; Marovt M; Mateeva V; Maul JT; Navarini AA; Nicolescu AC; Ratzinger G; Pavlovsky L; Sanzharovskaya M; Szegedi A; Reich A
J Eur Acad Dermatol Venereol; 2024 Jan; ():. PubMed ID: 38279888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
